Gain Therapeutics (NASDAQ:GANX) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Gain Therapeutics (NASDAQ:GANX) released its quarterly earnings data on Tuesday. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03, Zacks reports.

Gain Therapeutics Stock Performance

Shares of NASDAQ:GANX traded up $0.17 on Tuesday, hitting $1.94. 173,077 shares of the company were exchanged, compared to its average volume of 795,000. The firm has a market capitalization of $82.53 million, a P/E ratio of -3.37 and a beta of 0.19. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.02. Gain Therapeutics has a 1-year low of $1.46 and a 1-year high of $4.34. The stock’s 50 day moving average price is $1.78 and its 200 day moving average price is $1.93.

Institutional Trading of Gain Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Sprott Inc. purchased a new stake in shares of Gain Therapeutics in the 4th quarter valued at approximately $39,000. Commonwealth Equity Services LLC purchased a new stake in shares of Gain Therapeutics during the fourth quarter worth approximately $41,000. Millennium Management LLC acquired a new stake in shares of Gain Therapeutics during the fourth quarter worth $45,000. JPMorgan Chase & Co. purchased a new position in Gain Therapeutics during the 3rd quarter worth $47,000. Finally, Engineers Gate Manager LP acquired a new position in shares of Gain Therapeutics during the fourth quarter worth about $47,000. Hedge funds and other institutional investors own 11.97% of the company’s stock.

Wall Street Analyst Weigh In

GANX has been the subject of a number of research analyst reports. Roth Capital reaffirmed a “buy” rating on shares of Gain Therapeutics in a research report on Tuesday, May 12th. Oppenheimer reaffirmed an “outperform” rating on shares of Gain Therapeutics in a research report on Wednesday, May 27th. Weiss Ratings downgraded shares of Gain Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 9th. HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Gain Therapeutics in a report on Wednesday, July 1st. Finally, Wall Street Zen upgraded Gain Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, June 21st. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.50.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.